GlassScriptPhysician profile
Jared C Donaldson
NPI 1699129064
$8,115.98
in general payments reported to CMS, 2019-2025
23 companies · $731 in 2025
The $731 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2021: $4,747 · 2022: $611 · 2023: $238 · 2024: $1,536 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,669 · Travel and Lodging: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,669.45 |
| Travel and Lodging | $834.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $5,024.53 | 2021-2024 | Photrexa Cross-Linking Kit, Idose |
| Alcon Vision LLC | $1,754.09 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Mallinckrodt Hospital Products INC. | $236.65 | 2021-2023 | Acthar |
| Tarsus Pharmaceuticals, INC. | $193.18 | 2024-2025 | Xdemvy |
| Amgen INC. | $142.07 | 2024-2025 | Tepezza |
| Rxsight INC | $128.28 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Harrow Eye, LLC | $122.07 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $121.01 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $56.17 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $40.52 | 2025 | Yutiq |
| Astellas Pharma US INC | $33.48 | 2025 | Izervay |
| Eyevance Pharmaceuticals LLC | $32.94 | 2022 | |
| Oyster Point Pharma, INC. | $28.02 | 2022 | |
| Ivantis, INC | $27.60 | 2021 | |
| Thea Pharma INC. | $24.70 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $24.40 | 2025 | Omni Surgical System |
| Eyepoint US, INC. | $24.04 | 2022 | |
| Genentech USA, INC. | $22.30 | 2024 | Vabysmo |
| Ocular Therapeutix, INC. | $21.27 | 2024 | Dextenza |
| Kala Pharmaceuticals, INC. | $17.62 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.75 | 2022 | |
| Coherus Oncology, INC. | $13.21 | 2023 | |
| Allergan, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Donaldson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.